WBR0930: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
|QuestionAuthor=William J Gibson | |QuestionAuthor=William J Gibson | ||
|ExamType=USMLE Step 1 | |ExamType=USMLE Step 1 | ||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|MainCategory=Pathology, Pharmacology | |||
|MainCategory=Pathology, Pharmacology | |||
|SubCategory=Hematology | |||
|Prompt=A 35 year old man is treated for acute promyelocytic leukemia with a sustained course of arsenic trioxide and All-trans-retinoic acid. If he develops a secondary malignancy due to this therapy, which of the following is most probable? | |Prompt=A 35 year old man is treated for acute promyelocytic leukemia with a sustained course of arsenic trioxide and All-trans-retinoic acid. If he develops a secondary malignancy due to this therapy, which of the following is most probable? | ||
|Explanation=Acute promyelocytic leukemia (APML) is rare subset of acute myeloid leukemia (AML). APML is characterized by a chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (RARA). These cells undergo a differentiation arrest, which can be reversed with all-trans retinoic acid. Histologically, APML is notable for leukemic cells containing rod-like cytoplasmic inclusions called “Auer rods”. Treatment of APML can precipitate release of these inclusion and cause DIC. | |Explanation=Acute promyelocytic leukemia (APML) is rare subset of acute myeloid leukemia (AML). APML is characterized by a chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (RARA). These cells undergo a differentiation arrest, which can be reversed with all-trans retinoic acid. Arsenic is thought to act by inhibiting the enzyme thioredoxin reductase.Histologically, APML is notable for leukemic cells containing rod-like cytoplasmic inclusions called “Auer rods”. Treatment of APML can precipitate release of these inclusion and cause DIC. | ||
'''Educational Objective:''' Angiosarcoma is a potential late complication of exposure to arsenic. | '''Educational Objective:''' Angiosarcoma is a potential late complication of exposure to arsenic. | ||
Line 10: | Line 28: | ||
First Aid 2013 page 223 | First Aid 2013 page 223 | ||
First Aid 2012 page 255 | First Aid 2012 page 255 | ||
Line 15: | Line 34: | ||
The carcinogenicity of arsenic. Pershagen G. Environ Health Perspect. 1981 Aug;40:93-100. Review. PMID: 7023936 | The carcinogenicity of arsenic. Pershagen G. Environ Health Perspect. 1981 Aug;40:93-100. Review. PMID: 7023936 | ||
|AnswerA=Gastric cancer | |AnswerA=Gastric cancer | ||
|AnswerAExp='''Incorrect:''' Gastric cancer can occur as a result of nistrosamine exposure. Nitrosamines are carcinogenic chemical compounds present in various foods, notably smoked meats. | |AnswerAExp='''Incorrect:''' Gastric cancer can occur as a result of nistrosamine exposure. Nitrosamines are carcinogenic chemical compounds present in various foods, notably smoked meats. | ||
Line 27: | Line 45: | ||
|AnswerEExp='''Correct:''' Angiosarcoma is a potential late complication of exposure to arsenic. | |AnswerEExp='''Correct:''' Angiosarcoma is a potential late complication of exposure to arsenic. | ||
|RightAnswer=E | |RightAnswer=E | ||
|WBRKeyword=Cancer, Chemotherapy, Side effect, Leukemia, | |WBRKeyword=Cancer, Chemotherapy, Side effect, Leukemia, Acute promyelocytic leukemia, Toxin | ||
|Approved=Yes | |Approved=Yes | ||
}} | }} |